Today, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment and prevention, according to IQVIA, an industry data provider. One widely used product, Descovy, has a sticker price of $26,000 annually. Generic versions of its predecessor, Truvada, whose patents have expired, now cost less than $400 a year.
David Swisher is among the people suing Gilead. He took the company’s H.I.V. drug Truvada for 12 years and developed kidney disease and osteoporosis. Gilead…
How a drugmaker profited by slow-walking a promising HIV therapy seattletimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seattletimes.com Daily Mail and Mail on Sunday newspapers.